LIVN Stock Overview
A medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
LivaNova PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.07 |
| 52 Week High | US$64.48 |
| 52 Week Low | US$32.48 |
| Beta | 0.90 |
| 1 Month Change | -15.31% |
| 3 Month Change | -26.91% |
| 1 Year Change | -32.39% |
| 3 Year Change | -59.52% |
| 5 Year Change | -27.27% |
| Change since IPO | 192.25% |
Recent News & Updates
With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For
Apr 11
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?
Mar 21
Investment In Obstructive Sleep Apnea And DTD Therapies Will Strengthen Future Market Position
Mar 11 Strategic focus on obstructive sleep apnea and cardiopulmonary advancements is key for revenue growth and market expansion.LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 28Recent updates
With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For
Apr 11Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?
Mar 21Investment In Obstructive Sleep Apnea And DTD Therapies Will Strengthen Future Market Position
Mar 11 Strategic focus on obstructive sleep apnea and cardiopulmonary advancements is key for revenue growth and market expansion.LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 28We Like These Underlying Return On Capital Trends At LivaNova (NASDAQ:LIVN)
Feb 25LivaNova PLC's (NASDAQ:LIVN) Price Is Right But Growth Is Lacking
Dec 28We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Nov 12LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 03LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
Oct 31LivaNova: Economics Should Start Making Sustained Improvements
Oct 18Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?
Oct 02LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares
Aug 21LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger
Jul 30At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?
Jul 04Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?
Jun 13LivaNova: Focus Is Paying Off
May 12These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong
Apr 08Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?
Feb 05A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)
Jan 15LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry
Dec 25LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company
Nov 29We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Nov 08At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?
Oct 16Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?
Sep 25Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal
Jul 26Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?
Jul 03An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued
Jun 09Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital
Apr 13What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?
Mar 13Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Feb 15Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up
Nov 25Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Oct 29LivaNova Loses Profit Momentum On Higher R&D Expense
Oct 13Shareholder Returns
| LIVN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.8% | -2.8% | -3.0% |
| 1Y | -32.4% | 3.2% | 4.6% |
Return vs Industry: LIVN underperformed the US Medical Equipment industry which returned 1.9% over the past year.
Return vs Market: LIVN underperformed the US Market which returned 5.9% over the past year.
Price Volatility
| LIVN volatility | |
|---|---|
| LIVN Average Weekly Movement | 6.9% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: LIVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LIVN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 2,900 | Vladimir Makatsaria | www.livanova.com |
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories.
LivaNova PLC Fundamentals Summary
| LIVN fundamental statistics | |
|---|---|
| Market cap | US$1.89b |
| Earnings (TTM) | US$63.23m |
| Revenue (TTM) | US$1.25b |
30.1x
P/E Ratio1.5x
P/S RatioIs LIVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIVN income statement (TTM) | |
|---|---|
| Revenue | US$1.25b |
| Cost of Revenue | US$381.26m |
| Gross Profit | US$872.17m |
| Other Expenses | US$808.94m |
| Earnings | US$63.23m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | 1.16 |
| Gross Margin | 69.58% |
| Net Profit Margin | 5.04% |
| Debt/Equity Ratio | 47.5% |
How did LIVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 10:57 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LivaNova PLC is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Polark | Baird |
| Matthew Miksic | Barclays |